Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Giannoukas, C. Karathanos, K. Nikolakopoulos, G. Georgiadis, C. Maltezos, C. Ioannou, S. Vasdekis, Georgios Trelopoulos (2018)
Tinzaparin in intermediate dose for the treatment of superficial vein thrombosis: Results from an observational multicenter study—SeVEN studyPhlebology, 33
H. Décousus, I. Quéré, E. Presles, F. Becker, M. Barrellier, M. Chanut, J. Gillet, H. Guénnéguez, Christine Leandri, P. Mismetti, O. Pichot, A. Leizorovicz (2010)
Superficial Venous Thrombosis and Venous ThromboembolismAnnals of Internal Medicine, 152
J. Beyer-Westendorf, S. Schellong, H. Gerlach, E. Rabe, J. Weitz, K. Jersemann, K. Sahin, R. Bauersachs (2017)
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial.The Lancet. Haematology, 4 3
G. Moneta (2011)
Superficial Venous Thrombosis and Venous Thromboembolism: A Large, Prospective Epidemiologic StudyYearbook of Vascular Surgery, 2011
Georgios Georgiadi and, Miltos Lazarides, Department of Vascular Surgery, University Hospital of Alexandroupolis, Greece; (4) Georgios Papadopoulos and Christos Ioannou
S. Kakkos, M. Gohel, N. Baekgaard, R. Bauersachs, S. Bellmunt-Montoya, S. Black, A. Cate‐Hoek, I. Elalamy, F. Enzmann, G. Geroulakos, A. Gottsäter, B. Hunt, A. Mansilha, A. Nicolaides, P. Sandset, G. Stansby, Esvs Committee, G. Borst, F. Gonçalves, N. Chakfé, R. Hinchliffe, P. Kolh, I. Končar, J. Lindholt, R. Tulamo, C. Twine, F. Vermassen, A. Wanhainen, Document Reviewers, M. Maeseneer, A. Comerota, P. Gloviczki, M. Kruip, M. Monreal, P. Prandoni, M. Céniga (2020)
European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
S. Cannegieter, E. Horváth-Puhó, M. Schmidt, O. Dekkers, L. Pedersen, J. Vandenbroucke, H. Sørensen (2015)
Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study.Blood, 125 2
M. Nisio, I. Wichers, S. Middeldorp (2013)
Treatment for superficial thrombophlebitis of the leg.The Cochrane database of systematic reviews, 4
Triantafillos Iordanidis-private vascular surgeon, Kozani, Greece; (15) Michalis Peroulis-private vascular surgeon
P. Prandoni, D. Tormene, R. Pesavento (2005)
High vs. low doses of low‐molecular‐weight heparin for the treatment of superficial vein thrombosis of the legs: a double‐blind, randomized trialJournal of Thrombosis and Haemostasis, 3
L. Duffett, C. Kearon, M. Rodger, M. Carrier (2019)
Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-AnalysisThrombosis and Haemostasis, 119
P. Frappé, P. Frappé, A. Buchmüller-Cordier, L. Bertoletti, L. Bertoletti, C. Bonithon‐Kopp, S. Couzan, P. Lafond, A. Leizorovicz, A. Merah, E. Presles, P. Preynat, Bernard Tardy, Bernard Tardy, Hervé Decousus, Hervé Decousus (2014)
Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community‐based studyJournal of Thrombosis and Haemostasis, 12
Konstantinos Goumas-private vascular surgeon
T. Lane, K. Sritharan, J Herbert, I. Franklin, Alun Davies (2015)
The disparate management of superficial venous thrombosis in primary and secondary carePhlebology, 30
H Decousus, I Quere, E Presles (2010)
Superficial venous thrombosis and venous thromboembolism: a large prospective epidemiological studyAnn Intern Med, 152
(1996)
Progression of superficial venous thrombosis to deep veins
K. Nikolakopoulos, S. Kakkos, C. Papageorgopoulou, I. Tsolakis (2018)
Extended-Duration Treatment of Superficial Vein Thrombosis of the Lower Limbs with TinzaparinVascular Specialist International, 34
C. Kearon, M. Carrier, C. Gu, S. Schulman, S. Bates, S. Kahn, I. Chagnon, D. Nguyen, Cynthia Wu, L. Rudd-Scott, J. Julian (2020)
Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized TrialSeminars in Thrombosis and Hemostasis, 46
M. Minno, P. Ambrosino, F. Ambrosini, E. Tremoli, G. Minno, F. Dentali (2016)
Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 14
Lauren Bell, Richard Berg, J. Schmelzer, Hong Liang, J. Mazza, R. Kanth, C. Bray, Calixto Zaldivar, S. Yale (2016)
Thromboembolic complications following a first isolated episode of superficial vein thrombosis: a cross-sectional retrospective studyJournal of Thrombosis and Thrombolysis, 43
C. Karathanos, D. Chatzis, Panagiotis Latzios, I. Papakostas, K. Goumas, A. Giannoukas (2021)
Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study – The SeVEN EXTension studyPhlebology, 36
J. Galanaud, C. Genty, M. Sevestre, D. Brisot, M. Lausecker, J. Gillet, C. Rolland, M. Righini, G. Leftheriotis, J. Bosson, I. Quéré (2010)
Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosisThrombosis and Haemostasis, 105
R. Bauersachs, H. Gerlach, A. Heinken, U. Hoffmann, F. Langer, T. Noppeney, D. Pittrow, J. Klotsche, E. Rabe (2021)
Management and Outcomes of Patients with Isolated Superficial Vein Thrombosis under Real Life Conditions (INSIGHTS-SVT).European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
C. Karathanos, K. Spanos, Vassileios Saleptsis, A. Tsezou, D. Kyriakou, A. Giannoukas (2016)
Recurrence of superficial vein thrombosis in patients with varicose veinsPhlebology, 31
H. Décousus, L. Bertoletti, P. Frappé, F. Becker, Asma Jaouhari, P. Mismetti, N. Moulin, E. Presles, I. Quéré, A. Leizorovicz (2011)
Recent findings in the epidemiology, diagnosis and treatment of superficial-vein thrombosis.Thrombosis research, 127 Suppl 3
JP Galanaud, C Genty, MA Sevestre (2011)
Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis: the OPTIMEV studyThromb Haemost, 105
L. Goldman, J. Ginsberg (2010)
Superficial phlebitis and phase 3.5 trials.The New England journal of medicine, 363 13
J. Galanaud, M. Sevestre, G. Pernod, S. Kahn, C. Genty, H. Terrisse, D. Brisot, J. Gillet, I. Quéré, J. Bosson (2017)
Long‐term risk of venous thromboembolism recurrence after isolated superficial vein thrombosisJournal of Thrombosis and Haemostasis, 15
A. Galeandro, P. Scicchitano, A. Zito, C. Galeandro, M. Gesualdo, F. Ciciarello, A. Cecere, A. Marzullo, V. Contursi, A. Annicchiarico, M. Ciccone (2014)
A three-dimensional electronic report of a venous echo color Doppler of the lower limbs: MEVeC®Vascular Health and Risk Management, 10
C. Karathanos, K. Spanos, V. Lachanas, A. Athanasoulas, A. Giannoukas (2017)
Patterns in the management of superficial vein thrombosisPhlebology, 32
B. Cosmi, M. Filippini, D. Tonti, Giampiero Avruscio, A. Ghirarduzzi, E. Bucherini, G. Camporese, Davide Imberti, G. Palareti (2012)
A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum)Journal of Thrombosis and Haemostasis, 10
F. Verlato, P. Zucchetta, P. Prandoni, G. Camporese, M. Marzola, G. Salmistraro, F. Bui, Romeo Martini, F. Rosso, G. Andreozzi (1999)
An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh.Journal of vascular surgery, 30 6
ObjectivesTo evaluate the risk of symptomatic venous thromboembolism (VTE) recurrence at 3 months in relation to treatment duration, according to baseline risk factor profiles, in patients with superficial vein thrombosis (SVT) treated with intermediate dose of tinzaparin.MethodsWe performed a pooled analysis on individual data from two prospective studies designed to assess the efficacy and safety of tinzaparin in intermediate dose (131 IU/kg) in patients with SVT. Treatment duration was at the treating physician’s discretion. All patients were followed up for at least 3 months.ResultsA total of 956 patients (65% female, mean age 58.7 ± 13.7 years) were included. The median treatment duration was 30 days (range, 3–200 days). History of deep vein thrombosis (DVT), location of SVT above the knee, and palpable induration were the only independent factors associated with prolonged treatment duration. During follow-up, 95.9% of patients were event free. Outcomes-related adverse events occurred in 39 (4.1%) patients and their median duration of treatment was 33 days (range, 7–200 days). Recurrent VTE events occurred in 33 patients, including 22 cases of SVT recurrence, 8 cases of DVT, and 1 case of pulmonary embolism. The median time to the event was 29 (6–113) days. Recurrent thromboembolic events were not related to treatment duration as occurred in 17 patients (51.5%) treated up to 30 days and in 16 patients (48.8%) received prolong treatment (p = .46). Length of thrombus at the index event was significantly associated with higher risk for VTE recurrence.ConclusionsIntermediate dose of tinzaparin for 30 days is an effective and safe treatment for SVT. The risk of recurrent VTE events may be higher in patients with greater amount of thrombus at index event.
Phlebology The Journal of Venous Disease – SAGE
Published: Apr 1, 2023
Keywords: Deep vein thrombosis; pulmonary embolism; superficial vein thrombosis; venous thromboembolism; low-molecular weight heparin
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.